000			03347nam a22004095i 4500
001			75705
003			ES-MaUEC
005			20230202101705.0
007			cr nn 008mamaa
008			100301s2006 xxu| s |||| 0|eng d
020			_a9780387449616
040			_aES-MaUEC
050		4	_aRS420 _b.O685 2006 EB
082	0	4	_a615
245	1	0	_aOptimizing the zDrug-Likey Properties of Leads in Drug Discovery _cedited by Ronald T Borchardt, Edward H Kerns, Michael J Hageman, Dhiren R Thakker, James L Stevens
260			_aNew York, NY _bSpringer International Publishing _c2006
300			_a1 recurso en línea (X, 512 p.) With CD-ROM.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
338			_aonline resource _bcr _2rdacarrier
490	1		_aBiotechnology: Pharmaceutical Aspects _vIV
520			_aDrug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, “drug-likeâ€{u0C32}operties refer to the moleculeâ€{u3830}hysicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aMedicamentos _xDiseño _9395061 _0comprobar BNE20070512840 _2embne
700	1		_aBorchardt, Ronald T. _eeditor literario _0Local _984243
700	1		_aKerns, Edward H. _eeditor literario _0Local _984244
700	1		_aHageman, Michael J. _eeditor literario _0Local _984245
700	1		_aThakker, Dhiren R _eeditor literario _984246 _0Local
700	1		_aStevens, James L _eeditor literario _984247 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-0-387-44961-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9780387449616
907			_a.b12813230 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b03-01-17 _cm _dz _ef _feng _gxxu _h0
945			_aRS420 .O685 2006 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11542615 _z06-04-17
999			_c75705 _d75705 _x1